Clinical Scorecard: Reduced Bone Material Strength Index Observed in Cushing's Syndrome Patients Post-Long-term Remission
At a Glance
Category
Detail
Condition
Endogenous Cushing's syndrome with hypercortisolism
Key Mechanisms
Glucocorticoid excess causing decreased bone formation, increased bone resorption, and altered bone material properties
Target Population
Adults in remission after treatment for endogenous Cushing's syndrome
Care Setting
Tertiary referral center outpatient clinics specializing in endocrine and bone diseases
Key Highlights
Bone mineral density (BMD) improves after remission but fracture risk remains elevated in Cushing's syndrome patients.
Bone material strength index (BMSi), measured by impact microindentation, is significantly lower in CS patients in remission compared to matched controls despite similar BMD.
Altered bone material properties may contribute to persistent bone fragility in CS patients even after long-term remission.
Guideline-Based Recommendations
Diagnosis
Assess bone health in CS patients using both BMD and bone material properties such as BMSi.
Confirm remission status by biochemical testing including 24-hour urinary free cortisol, midnight salivary cortisol, and dexamethasone suppression test.
Management
Follow Endocrine Society clinical practice guidelines for treatment and monitoring of CS and post-remission care.
Consider bone quality assessment beyond BMD to evaluate fracture risk in CS patients.
Monitoring & Follow-up
Perform periodic bone mineral density measurements and vertebral fracture assessments.
Use impact microindentation (OsteoProbe®) to monitor bone material strength index in CS patients during remission.
Risks
Persistent increased fracture risk despite normalization of BMD after remission.
Bone fragility related to altered bone material properties independent of BMD.
Patient & Prescribing Data
Adults aged 18 to 85 years in remission from endogenous Cushing's syndrome for at least 6 months.
Hydrocortisone replacement therapy used post-treatment does not appear to affect bone material strength index.
Clinical Best Practices
Include bone material strength index measurement via impact microindentation as part of comprehensive bone health assessment in CS patients.
Recognize that normal or improved BMD does not exclude persistent bone fragility in CS remission.
Manage fracture risk in CS patients by addressing both bone density and bone quality factors.
by Manuela Schoeb, Paula J C Sintenie, Leontine E H Bakker, Nienke R Biermasz, Femke M van Haalen, Michiel F Nijhoff, Friso de Vries, Elizabeth M Winter, Alberto M Pereira, Natasha M Appelman-Dijkstra
